Detoxamin, the Only Chelation Suppositories That Have Been Proven in Rigorous Scientific & Clinical Studies

Heavy metal exposures in the twenty-first century are an established global health concern. The FDA has approved EDTA as a chelation agent for the removal of heavy metals. It has been placed on the FDA .“Generally Recognized as Safe.” (GRAS) list for the past sixty years. Extensive national and international clinical experiences demonstrate that acute and chronic human exposure to a wide range of heavy metals can be treated with considerable efficacy using EDTA. It is widely administered, with considerable cost to the patient, as an intravenous (IV) solution, which entails 15 to 30 sessions in a physician.’s office, taking two to five hours per visit. The trans-rectal delivery of several pharmacological agents is well established. Detoxamin Chelation Suppositories are the only product of its kind that has scientific & clinical proof showing its effectiveness.

edta chelation therapy

Detoxamin Chelation Suppositories Groundbreaking EDTA Suppository Science

Therefore, using a rat animal model, Detoxamin Chelation Suppositories research team set out to determine if the rectal administration of it's proprietary EDTA matrix formula is absorbed, resulting in significant blood and tissue levels. The pharmacodynamic effects of therapeutic agents differ widely in their route of administration, penetration, absorption, and distribution in body tissues. For medicinal agents to act, they must be absorbed and transported to the appropriate tissue or organ, penetrate to the responding cell surface or sub-cellular and interstitial space, and elicit a response or alter ongoing processes.¹  The parenteral and intramuscular injectable forms of EDTA are well absorbed but painful, and not very practical for routine usage.²  Oral forms of EDTA have been shown to be poorly absorbed (2% to 5%), and topical and subcutaneous forms have been reported as not being  absorbed at all.³, ⁴, ⁵, ⁶, ⁷, ⁸, ⁹, ¹⁰

IV EDTA Blood Levels, Out of the Body Rapidly

Although IV EDTA dosing is well characterized and has been used for decades, prior to Detoxamin's Chelation Suppositories groundbreaking study, little science was known about the absorption and bio-availability of Detoxamin. In an effort to elucidate the absorption characteristics of Detoxamin Chelation Suppositories unique, proprietary CaNa2  EDTA matrix, a rat model was chosen.

Here you see the blood levels via administration of IV EDTA, notice the EDTA is being introduced rapidly, and the body will eliminate the EDTA within about 2 hours. Note here that Detoxamin's EDTA matrix is in the body over eight hours. This is important since toxic metals are stored primarily in the soft tissues, the longer EDTA is in the body, the better for deep-tissue cleansing of toxic metals, just one of the reasons why Detoxamin Chelation Suppositories are preferred by so many.

EDTA levels in blood over time following intravenous administration of EDTA.

Detoxamin Chelation Suppositories Blood Levels, Eight Hours or More

EDTA is not bio-transformed in the body, or metabolized. It is excreted in hair, urine, feces, saliva, and perspiration. This study shows that animals excreted 47.3% and 30.3% of dosed radioactivity in urine during the 8 hours following intravenous and rectal dosing, respectively. The 30.3% excretion of EDTA in the urine corresponds closely to Detoxamin's bioavailability calculated from the blood levels (36.3%). Blood samples were taken over an 8-hour period, and during this time, Detoxamin Chelation Suppositories showed high levels of absorbed ETDA with no apparent elimination phase observed. If further blood samples had been taken, the bioavailability calculated for Detoxamin Chelation Suppositories EDTA matrix would have undoubtedly been much higher, since the bioavailability calculation presented here only used up to 8- hour blood level data.

Here you see Detoxamin's unique EDTA matrix with blood levels of 8 hours, or more. This, combined with less metabolic competition (taken while you sleep is less metabolically competitive for EDTA to work), allows for deep-tissue heavy metal cleansing.

EDTA levels in blood over time following administration of Detoxamin's EDTA matrix

High EDTA Absorption & Lasting Levels

Detoxamin Chelation Suppositories groundbreaking study clearly shows its proprietary matrix formula of Ca Na2 EDTA has been effectively absorbed from the lower enteral route in rats, through the anal portal into the rectum or lower intestine to reach blood and tissue levels via Detoxamin Chelation Suppositories.

Intravenous dosing resulted in greater elimination of radioactivity in urine at the 0 to 4 hour time point, but the percent of dose recovered drastically decreased by the 4 to 8 hour time point, while the level of recovery was relatively steady at both time points following Detoxamin. The slow and consistent movement of Detoxamin Chelation Suppositories rectal administration may have lesser toxicity since there are significant blood and tissue levels to chelate metals without a high dose EDTA IV drip over many hours. These data point to the ability of Detoxamin Chelation Suppositories to deliver a continuous lower dose concentration of EDTA for longer periods of time compared with IV administration, allowing EDTA to bind metals efficiently and effectively.

Detoxamin EDTA Matrix Tissue Absorption


1. University of the SC/Remington. The science and practice of pharmacy. Columbia, S.C.: Lippincott Williams & Wilkins/Wolters Kluwer, 21:2006.
2. Foreman H. Metal Binding Med, Proc Symposium, Philadelphia, 1959. 1960;82-94.
3. Sbrova J Teisinger J, Arc. Gewerbepathol. 1957;15:572.
4. Foreman H. Metal Binding Med, Proc Symposium, Philadelphia, 1959. 1960;82-94.
5. Foreman H, Vier M, Magee M. The metabolism of C14 labeled ethylenediamine tetraacetic acid in the rat, J Biol Chem.1953;203:1045.
6. Yang, SS. Ethylenediaminetetraacetate, Disodium and Calcium Disodium Salts. Seventeenth Report of the Joint FAO/WHO Expert Committee on Food Additives. Wld Hlth Org.techn. rep. ser., 1974, No. 539; FAO Nutrition Meetings Report Series, 1974, No. 53. http://www.inchem.org/documents/jecfa/jecmono/v05je25.htm
7. Cleton F, Turnbull A, Finch, CA. Synthetic chelating agents in iron metabolism. J Clin Invest. 1963 March; 42(3): 327-337.
8. Foreman H, Trujillo TT. Synthetic chelating agents in iron metabolism. J Lab Clin Med. 1954 Apr;43(4):566-571.
9. MacPhail AP, Bothwell TH, Torrance JD, et al. Factors affecting the absorption of iron from Fe(III)EDTA. Br J Nutr. 1981 Mar;45(2):215-227.
10. Bjarnason I, O.’Morain C, Levi AJ, Peters TJ. Absorption of 51 chromium-labeled ethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterol. 1983 Aug;85(2):318-322.

  • No products in the cart.